Dr. Nakada is Vice President, Venture Investments at Johnson & Johnson Innovation – JJDC. She has more than 30 years of experience in the pharmaceutical industry, starting her career at the laboratory bench at Centocor and moving to a research leadership role before Centocor’s acquisition by Johnson & Johnson. She later transitioned to Janssen Business Development and joined Johnson & Johnson Innovation (JJDC) in 2013.

Dr. Nakada has an A.B. in biology from Harvard College and a Ph.D. in pharmacology from the University of Pennsylvania. She has authored 62 peer-reviewed publications and 14 book chapters and is a past reviewer for the NIH Pharmacology Study Section. She is currently on the boards of ONL Therapeutics, Navitor and a stealth NewCo and is a board observer for Aetion, Iterative Health, Arkuda Therapeutics and Rome.